These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25397426)

  • 21. Validation of the Elecsys® HIV combi PT assay for screening and reliable early detection of HIV-1 infection in Asia.
    Tao CM; Cho Y; Ng KP; Han X; Oh EJ; Zainah S; Rozainanee MZ; Wang LL
    J Clin Virol; 2013 Sep; 58(1):221-6. PubMed ID: 23809476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
    Arribas J; Rizzardini G; Arasteh K; Zurawski C; Dietz C; Pontani D; Garner W; Nguyen T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19805. PubMed ID: 25397549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
    Pinnetti C; Lorenzini P; Cozzi-Lepri A; Sandrine O; Tommasi C; Zaccarelli M; Perno CF; Capobianchi MR; Girardi E; Antinori A; Ammassari A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19809. PubMed ID: 25397553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ARCHITECT® HIV Ag/Ab Combo assay: correlation of HIV-1 p24 antigen sensitivity and RNA viral load using genetically diverse virus isolates.
    Brennan CA; Yamaguchi J; Vallari A; Swanson P; Hackett JR
    J Clin Virol; 2013 Jun; 57(2):169-72. PubMed ID: 23485348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma.
    Bentsen C; McLaughlin L; Mitchell E; Ferrera C; Liska S; Myers R; Peel S; Swenson P; Gadelle S; Shriver MK
    J Clin Virol; 2011 Dec; 52 Suppl 1():S57-61. PubMed ID: 21995929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy.
    Cozzi-Lepri A; Lo Caputo S; Maggiolo F; Antinori A; Ammassari A; Marchetti G; Mastroianni C; Gori A; Di Perri G; Angarano G; Carbone A; Monforte Ad;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19775. PubMed ID: 25397519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Darunavir-based dual therapy in HIV experienced patients.
    Sterrantino G; Zaccarelli M; Di Biagio A; Rosi A; Bruzzone B; Cicconi P; Carli T; Biondi ML; Antinori A; Bartolozzi D; Penco G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19782. PubMed ID: 25397526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
    Elzi L; Erb S; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2012 Sep; 172(17):1313-21. PubMed ID: 22892835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain volumetrics differ by Fiebig stage in acute HIV infection.
    Bolzenius J; Sacdalan C; Ndhlovu LC; Sailasuta N; Trautmann L; Tipsuk S; Crowell TA; Suttichom D; Colby DJ; Phanuphak N; Chan P; Premeaux T; Kroon E; Vasan S; Hsu DC; Valcour V; Ananworanich J; Robb ML; Ake JA; Pohl KM; Sriplienchan S; Spudich S; Paul R;
    AIDS; 2023 May; 37(6):861-869. PubMed ID: 36723491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Field evaluation of the Abbott ARCHITECT HIV Ag/Ab Combo immunoassay.
    Kfutwah A; Lemée V; Ngono HV; De Oliveira F; Njouom R; Plantier JC
    J Clin Virol; 2013 Dec; 58 Suppl 1():e70-5. PubMed ID: 24342480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment.
    Dijkstra M; Prins H; Prins JM; Reiss P; Boucher C; Verbon A; Rokx C; de Bree G
    BMJ Open; 2021 Nov; 11(11):e048582. PubMed ID: 34845066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
    Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation.
    Crowell TA; Ritz J; Coombs RW; Zheng L; Eron JJ; Mellors JW; Dragavon J; van Zyl GU; Lama JR; Ruxrungtham K; Grinsztejn B; Arduino RC; Fox L; Ananworanich J; Daar ES;
    Clin Infect Dis; 2021 Aug; 73(3):e643-e651. PubMed ID: 33382405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early clinical response and presence of viral resistant minority variants: a proof of concept study.
    Callegaro A; Di Filippo E; Astuti N; Ortega PA; Rizzi M; Farina C; Valenti D; Maggiolo F
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19759. PubMed ID: 25397504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative evaluation of the VIDAS HIV DUO Ultra assay for combined detection of HIV-1 antigen and antibodies to HIV.
    Bourlet T; Pretis C; Pillet S; Lesenechal M; Piche J; Pozzetto B
    J Virol Methods; 2005 Aug; 127(2):165-7. PubMed ID: 15967238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard.
    Miedouge M; Grèze M; Bailly A; Izopet J
    J Clin Virol; 2011 Jan; 50(1):57-60. PubMed ID: 20926337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.